Compare Chevron Corp (CVX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs TG Therapeutics Inc — how do they compare? Chevron Corp trades at $212.04 (market cap $414.98B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Chevron Corp is far larger — about 50.9× TG Therapeutics Inc's market cap, and Chevron Corp pays a 3.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and TG Therapeutics Inc for 16 Days on average.
| CVX | TGTX | |
|---|---|---|
Market Cap | $414.98B | $8.16B |
Volume | 7,575,112 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $217.73 | $59.06 |
52-Week Low | $146.72 | $26.94 |
Typical Hold Time | 101 Days | 16 Days |
Enterprise Value | $443.52B | $8.37B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $205.19, down 1.17% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. Revenue declined to $184.43B in 2025, but a rebound to $208.7B is projected for 2026. Analyst consensus is a Buy with a $208.31 price target, and the company maintains a strong balance sheet with $6.79B in cash.
CVX presents a mixed outlook; earnings beats and a favorable analyst consensus support upside, but declining revenue and net income margins pose risks. High oil prices and strategic investments, like the $13.8B Argentina project, offer growth potential, yet geopolitical tensions and volatile energy markets remain headwinds for shareholders.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
